Home
Companies
Eli Lilly and Company

Eli Lilly and Company

Company

Also known as: Eli Lilly, Eli Lilly and Co., Lilly, Lilly Oncology

Company Profile

Eli Lilly and Company is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876, it sells products in about 125 countries and is publicly traded on the NYSE as LLY. Its major products include tirzepatide (Mounjaro and Zepbound) and other therapies in diabetes, oncology, and immunology.

Website: https://www.lilly.com
Headquarters: Indianapolis, Indiana, US
Founded: 1876
Stock Ticker: NYSE:LLY

Related News

Three Manufacturers Supply 90% of Global Insulin as Biosimilars Erode Oligopoly

Jun 28, 2026

The global insulin drugs and delivery devices market is dominated by three manufacturers supplying roughly 90% of volume, with biosimilar entry slowly eroding this oligopoly. The market is projected to see continued growth driven by rising diabetes prevalence, while pricing pressure from biosimilars and government policies accelerates. In the Middle East, the recombinant human insulin market is projected to expand at a 6–8% CAGR through 2035.

AstraZeneca Advances Oral GLP-1 Drug and Defends Diabetes Patent in Australia

Jun 19, 2026

AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.

New GLP-1 Competition, FDA Approval, and Genomic Atlases Advance Drug Development

Jun 15, 2026

At the ADA Scientific Sessions, Novo Nordisk's Wegovy pill surpassed 3 million prescriptions within five months, while Structure Therapeutics and AstraZeneca shared mid-stage GLP-1 data targeting a 2029 launch. The US FDA approved TRUQAP as the first targeted treatment for PTEN-deficient metastatic prostate cancer, reducing disease progression risk by 19% in the CAPItello-281 trial. Meanwhile, two major genomic atlas projects—a 4,098-genome infant gut bacteria catalog and Basecamp Research's Trillion Gene Atlas—aim to advance precision probiotics and AI-driven drug discovery, respectively.

Sangamo Therapeutics Retains Raymond James to Explore Strategic Alternatives

Jun 08, 2026

Sangamo Therapeutics has retained Raymond James to evaluate strategic alternatives to advance its pipeline and maximize stakeholder value. Key assets include the BLA-ready Fabry disease gene therapy ST-920, the STAC-BBB capsid platform generating $88M in fees to date, and multiple neurology programs. No transaction has been agreed and no timetable has been set.

Beam Therapeutics Gets Buy Initiation, Accelerated FDA Pathway for BEAM-302

Jun 08, 2026

Canaccord Genuity initiated Beam Therapeutics with a buy rating and $74 price target, highlighting near-term catalysts. Beam reached an agreement with the FDA on an accelerated approval pathway for its BEAM-302 AATD therapy, which showed early clinical proof-of-concept for in vivo base editing. The company plans a BLA for risto-cel and a pivotal plan for BEAM-302 in early 2026.

Oncology Drug Market Sees Strong Growth Amid Patent Cliffs and Novel Modality Shifts

Jun 05, 2026

Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07613307	A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting	NOT_YET_RECRUITING	PHASE3
NCT07613294	A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk	NOT_YET_RECRUITING	PHASE3
NCT07612293	STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection	NOT_YET_RECRUITING	NA
NCT07612267	A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication	NOT_YET_RECRUITING	PHASE4
NCT07607483	A Study of LY4065967 in Healthy Participants	NOT_YET_RECRUITING	PHASE1
NCT07602582	A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).	NOT_YET_RECRUITING	PHASE3
NCT07598370	A Study of LY3439539 in Participants With Alzheimer's Disease	NOT_YET_RECRUITING	PHASE1
NCT07592572	A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants	NOT_YET_RECRUITING	PHASE1
NCT07589608	A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight	NOT_YET_RECRUITING	PHASE2
NCT07589595	A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)	NOT_YET_RECRUITING	PHASE2